Compare · NEO vs ULS
NEO vs ULS
Side-by-side comparison of NeoGenomics Inc. (NEO) and UL Solutions Inc. (ULS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEO and ULS operate in Precision Instruments (Health Care), so they compete in similar markets.
- ULS is the larger of the two at $15.64B, about 7.9x NEO ($1.97B).
- ULS has been more active in the news (14 items in the past 4 weeks vs 5 for NEO).
- NEO has more recent analyst coverage (25 ratings vs 7 for ULS).
- Company
- NeoGenomics Inc.
- UL Solutions Inc.
- Price
- -
- -
- Market cap
- $1.97B
- $15.64B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Precision Instruments
- Precision Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 14
- Recent ratings
- 25
- 7
NeoGenomics Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Latest NEO
- Amendment: SEC Form SCHEDULE 13G/A filed by NeoGenomics Inc.
- NeoGenomics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by NeoGenomics Inc.
- SEC Form 8-K filed by NeoGenomics Inc.
- NeoGenomics Reports Third Quarter 2026 Results
- NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
- NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
- NeoGenomics upgraded by BTIG Research with a new price target
- SEC Form 4 filed by NeoGenomics Inc.
- SEC Form 8-K filed by NeoGenomics Inc.
Latest ULS
- JSL Group Residential Properties Become First Globally to Earn Two New UL Solutions Building Verification Marks
- UL Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- UL Solutions Inc. Enters Definitive Agreement to Acquire Worldly Holdings Inc., Expanding ULTRUS® Software Platform
- Amendment: SEC Form SCHEDULE 13G/A filed by UL Solutions Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by UL Solutions Inc.
- UL Solutions Announces Quarterly Dividend
- UL Solutions to Attend Upcoming Investor Conferences
- UL Solutions Collaborates on Cross-Industry Initiative to Modernize Life Science Regulated Training
- UL Solutions Expands High-Wind Testing Services in North America
- President and CEO Scanlon Jennifer F. sold $937,904 worth of shares (12,500 units at $75.03) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 114,224 units (SEC Form 4)